Patient P-03099

Synthetic patientONX-7 · Day 148 · 25–34 · F · baseline S17Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

74%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S17
Day 55 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 102 CR-01 recommended — Clinician Review CR-01
Day 103 Patient accepted — Started CR-01 in the companion
Day 108 Deterioration detected before clinical escalation — Clinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 55.

Primary contributors, last 14 days

GI instability+16
Toxicity-15
Nutritional resilience-10
Treatment adherence+6
Inflammatory activity+5

What helped?

Clinician Review CR-01Day 102
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

70%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 68 and rising
- WearableSleep 5.4 h, below personal baseline
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 59
- WearableHRV 23 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓45
- WearableResting HR 80 bpm
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.9 · butyrate capacity 39/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 25 ms
Sleep: 5.9 h
Steps: 6,272
Resting HR: 79 bpm

Daily log: GI score 68, nutritional resilience 35, adherence 70.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03191	44%	S19	GI-04	improved	51
P-03166	43%	S20	CR-01	improved	62
P-03225	40%	S19	GI-04	improved	50
P-03031	36%	S16	CR-01	improved	49
P-03226	35%	S05	GI-04	improved	43
P-03357	35%	S02	CR-01	improved	50
P-03382	35%	S01	GI-04	improved	56
P-03465	35%	S17	CR-01	improved	65
P-03201	34%	S15	GI-04	improved	68
P-03049	33%	S14	GI-04	improved	49
P-03090	33%	S02	GI-04	improved	48
P-03341	33%	S14	NP-02	improved	49